[13C6]-Irinotecan

[13C6]-Irinotecan is a stable isotope-labeled derivative of Irinotecan, which is a topoisomerase I inhibitor commonly used in chemotherapy for treating various types of cancer. The stable isotopes of carbon used in this compound are non-radioactive and do not affect the biological activity of the parent drug. [13C6]-Irinotecan is mainly used in pharmacokinetic and metabolic studies to track the biodistribution and metabolism of Irinotecan in vivo. The chemical structure of [13C6]-Irinotecan consists of a carbocyclic lactone ring, a pentacyclic ring system, and a side chain containing a 7-ethyl-10-hydroxycamptothecin moiety. The presence of stable isotopes in [13C6]-Irinotecan allows for precise and accurate detection and quantification of the drug in biological samples using analytical techniques like mass spectrometry. In preclinical studies, [13C6]-Irinotecan has been shown to have similar pharmacokinetic properties as the parent drug, making it a useful tool for assessing the oral bioavailability, plasma clearance, and distribution of Irinotecan in animal models. Additionally, [13C6]-Irinotecan has been used in clinical studies to investigate the pharmacokinetics and metabolism of Irinotecan in cancer patients. In conclusion, [13C6]-Irinotecan is a valuable tool for studying the pharmacokinetics and metabolism of Irinotecan in preclinical and clinical settings. Its stable isotopes provide accurate and precise measurements, making it an indispensable compound in drug development and cancer research.